Although regenerative therapies are relatively new, more & more hospitals are incorporating cell and gene treatments to treat patients, driving up investment in this sector. World-wide 30 cell and gene therapies have been authorised for large scale production. Looking to the future, biopharmaceutical and biotech companies, and other stakeholders, including regulators and researchers will need to collaborate to develop a new pipeline of research from biological concept to medical practice.

會議將邀請國內外頂尖的細胞治療基礎研究和臨床專家，瞄準細胞治療研究的最新研究動態和進展， 圍繞上市從細胞治療的臨床監管、治療規範、細胞治療安全性，新型細胞治療技術、實體瘤治療、腫瘤免疫檢查點抑製劑、間充質乾細胞、幹細胞移植治療、基因編輯與細胞治療、細胞治療生產製造工藝等熱門議題進行討論。

With more than 3,500 attendees, speakers, exhibitors, sponsors, and media, the meeting brings together everyone from senior scientists to trainees to discover, share, and network with leading innovators in the stem cell community.

亞洲生技產業最大盛事，第十六屆台灣生技月系列活動之一【台灣生物科技大展】將在7月19日至22日於台北南港展覽館熱鬧開幕。今年展覽吸引中國、日本、韓國、澳洲、德國、瑞士、美國、加拿大等國家地區生技業者大陣仗來台參展，全館聚焦產業特性，以雙層展廳專業劃分12大主題區，共計約35間上市興櫃企業600參展商、1400攤位，規模歷年之最。